By Jennifer Ahlstrom | Posted - Mar 6th, 2017





Clinical Trial: Ibrutinib with Pomalidomide and Dexamethasone for Relapsed/Refractory Myeloma Patients

Ibrutinib is a new drug being studied to treat myeloma and is a Bruton's Tyrosine Kinase (BTK) Inhibitor. The drug targets BTK, an enzyme necessary for the development of fully functional B-cells. The BTK enzyme is known to be more prolific in cancerous B-cells.  Malignant myeloma cells have increased BTK expression compared to non-malignant cells, so blocking BTK activity in myeloma has been shown to inhibit growth of tumors and release of osteoclast-derived tumor growth factors. Ibrutinib has been studied since the 1990's and has been used in many clinical trial in the last few years. 

A Phase I clinical trial will study a new drug called ibrutinib in combination with pomalidomide (an immunomodulator) and dexamathasone (a steroid.)

The Phase II study will be divided into two groups for relapsed/refractory myeloma patients:

  • Ibrutinib/pomalidomide/dex
  • Placebo/pomalidomide/dex

There are 5 locations for this trial. 

To find the clinical trial on SparkCures, click here:

Ibrutinib/Pom/Dex Clinical Trial

Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.


Add a Comment



Thanks to our Myeloma Crowd Community sponsors:

.                         .       .